Sarcopenia
Conditions
Keywords
Home exercise, Resistance exercise, Exercise, Krill oil, Muscle strength, Neuromuscular function, Physical function
Brief summary
The aim of this study is to determine whether krill oil supplementation enhances effects of a pragmatic resistance exercise programme on adaptations in muscle strength, mass, function and neuromuscular function in sedentary older adults. Hypothesis - krill oil supplementation will enhance the beneficial effects of resistance exercise on muscle strength, function, mass and neuromuscular function in sedentary older adults.
Interventions
DIETARY_SUPPLEMENTVegetable oil
Mixed vegetable oil
DIETARY_SUPPLEMENTKrill oil
Superba Krill Oil
OTHERHome-based resistance exercise
Home based resistance band and body weight exercise
Sponsors
University of Glasgow
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
All supplements will be matched for taste and look
Intervention model description
1:1 parallel group design
Eligibility
Sex/Gender
ALL
Age
60 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Over the age of 60 years * scoring a low level of physical activity based on international physical activity questionnaire (not meeting the recommend physical activity which is at least 600 MET-min per week).
Exclusion criteria
* Diabetes * severe cardiovascular disease * seizure disorders * uncontrolled hypertension (\>150/90mmHg at baseline measurement) * cancer or cancer that has been in remission \<5 years * ambulatory impairments which would limit ability to perform assessments of muscle function * dementia * taking medication known to affect muscle (e.g. steroids) * have an implanted electronic device (e.g. pacemaker/defibrillator/insulin pump) * on anticoagulant therapy * allergies to seafood * regular consumption of more than 1 portion of oily fish per week * already taking fish or krill oil or other n3 PUFA supplements * femoral neck fracture or other severe of hip or knee operations * stroke * Parkinson's disease * COPD * kidney disease * hyperlipidaemia * obesity * osteoporosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nueromuscular Junction (NMJ) transmission instability | Change from baseline to 16 weeks | NMJ transmission instability will be measured by iEMG |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 30s chair stand test | Change from baseline to 16 weeks | measuring the functional abilities |
| Gait speed | Change from baseline to 16 weeks | measuring the functional abilities |
| Force steadiness during submaximal isometric knee extensor contractions | Change from baseline to 16 weeks | Steadiness of force whilst contracting |
| Knee extensor maximal torque | Change from baseline to 8 16 weeks | Knee extensor maximal torque will be measured by a load cell |
| Grip strength | Change from baseline to 16 weeks | Grip strength will be measured by handgrip dynamometer |
| Muscle thickness | Change from baseline to 16 weeks | Vastus Lateralis muscle thickness will be measured by ultrasound |
| Red Blood Cell Omega-3 levels | Change from baseline to 16 weeks | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Stance (%GC) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Step/ Extremity Ratio | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Toe In / Out (deg) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Distance (cm) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Ambulation Time (sec) | Change from baseline to 16 weeks | — |
| Velocity (cm/sec) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Step Time (sec) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Number of Steps | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Cadence (Steps/Min) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Step Time Differential (sec) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Step Length Differential (cm) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Cycle Time Differential (sec) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Mean Normalized Velocity | Change from baseline to16 weeks | Measured during a 4m walk using a gaitrite mat |
| Cycle Time (sec) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Step Length (cm) | Change from baseline to16 weeks | Measured during a 4m walk using a gaitrite mat |
| Stride Length (cm) | Change from baseline to16 weeks | Measured during a 4m walk using a gaitrite mat |
| H-H Base Support (cm) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Single Support (%GC) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Double Support (%GC) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
| Swing (%GC) | Change from baseline to 16 weeks | Measured during a 4m walk using a gaitrite mat |
Countries
United Kingdom
Outcome results
None listed